The CEO of Sanofi-Aventis, Chris Viehbacher is very keen for a deal with Genzyme. But investors, who are looking for a good payout from the deal, need to realize that Chris is a cautious person and keeps a lot of things in mind before the deal is completed.

Chris is a veteran in the pharma industry and has worked at GlaxoSmithKline for 20 years. He is also the first non-French to head Sanofi, which he joined in the year 2008.

Experts also feel that he is the right person, who can manage this deal and many investors are also impressed by his track record.

Chris also stressed that he was not willing to pay more amount than required for an acquisition. Analysts have already stressed that Sanofi will be placing a bid of $18.7 billion for U.S. biotech firm, Genzyme.

They are of the opinion that Genzyme is the correct target for Sanofi and they also pointed that the bid price is also reasonable.

Chris is also credited with streamlining research and development at Sanofi and making the overall systems more efficient. He is also planning to cut almost 4,000 positions by 2013. He has received a lot of support from investors, who have appreciated him for his working style.

This will also be the biggest deal for Sanofi after it merged with Aventis in 2004.